| My Account | Subscribe | Contact Us | Help |
Home
Diabetes Health
Diabetes Health Professional
- The Starfish Story, Diabetes, and the Poorest Nation in the World
Even drops in the bucket make a difference
- Flying on Insulin
It has been 22 years since Air Canada pilot Steve Steele was grounded with type 1
- Following Dr. Bernstein on Holiday
A traveling couple tries to stick to low carbs
- Sleep Apnea and Diabetes
Here’s something to make you sit up and take notice (maybe 100 times a night): 23 percent of type 2s have obstructive sleep apnea.
The must-have resource for physicians, educators and medical professionals who focus on the treatment of diabetes.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
Latest Metformin Articles
Glyburide/Metformin Combination Tablet Delivers Surprising Results
1 March 2004
Who would have guessed that taking two diabetes drugs combined in one tablet would offer greater glucose-lowering benefits than taking the same two drugs in separate but still co-administered tablets?
A glyburide/metformin tablet, marketed in the United States as Glucovance, delivered a significantly greater reduction in A1C than a prior regimen of glyburide co-administered with metformin.
According to a study from Bristol-Myers Squibb and the Ochsner Clinic Foundation in New Orleans, the effect was especially significant when a patient’s baseline A1C level was 8%.
The therapy was tested in 950 patients—471 of whom received glyburide co-administered with metformin. The average A1C decrease for the combination tablet group was 2.02%, compared with a decrease of 1.49% for glyburide co-administered with metformin, despite the fact that the patients receiving the combination tablet received lower doses of the medications.
The study data were obtained from retrospective pharmacy claims data and corresponding laboratory results from a usual-care setting.
Diabetes, Obesity and Metabolism, November 2003
Share on Facebook
Share on MySpace 
Share on Digg
You May Also Be Interested In...
147 comments - 29 Nov 2007
111 comments - 22 Sep 2008
82 comments - 14 Aug 2008
52 comments - 18 Jan 2008
Comments
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register..
Register your Diabetes Health Username here.
Have Your Say...